Friday 6 November 2026
Export INSP’s income statement to Excel — free account
Inspire Medical Systems, Inc.
INSP Healthcare Medical Devices
Inspire Medical Systems, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $912.0 million, up 13.6% from fiscal 2024.
- Revenue
- −7.93%
- EPS
- −348.0%
- Free cash flow
- −33.1%
Quarter to September 2026, against a year earlier
64.22
2.31
−3.47%
Follow INSP
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
19.95 | 9.57 | 11.39 | 18.37 |
+8 more quarters Free account |
P/S ratio |
2.28 | 1.43 | 1.62 | 2.97 | |
P/FCF ratio |
20.50 | 10.99 | 15.31 | 34.52 | |
P/Operating CF |
43.22 | 55.38 | 115.21 | 51.62 | |
P/B ratio |
2.43 | 1.56 | 1.87 | 3.47 | |
Price to Tangible BV |
2.43 | 1.56 | 1.87 | 3.47 | |
EV/Sales |
1.92 | 1.09 | 1.32 | 2.64 | |
EV/EBITDA |
50.93 | 13.93 | 18.45 | 38.86 | |
EV/Operating CF |
12.51 | 6.21 | 8.84 | 20.60 | |
EV/FCF |
17.25 | 8.33 | 12.47 | 30.71 | |
Quick Ratio |
4.45 | 5.96 | 4.35 | 4.46 | |
Current Ratio |
6.45 | 8.55 | 6.34 | 6.08 | |
Net Debt/EBITDA |
13.69 | (83.38) | (76.67) | (6.22) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.00 | 1.04 | 1.11 | 1.06 | |
Operating CF/Net income |
(1.90) | 73.97 | (1.14) | 0.39 | |
Capex/Depreciation |
(1.58) | (2.10) | (2.02) | (3.09) | |
Interest Coverage |
— | — | — | 365.96 | |
Research and Development Expense of Revenue |
10.73% | 12.31% | 12.62% | 9.27% | |
Selling, General and Administrative Expense of Revenue |
89.21% | 73.42% | 74.40% | 60.19% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
13.02% | 15.57% | 15.00% | 10.41% | |
Graham Net Nets |
0.25 | 0.40 | 0.30 | 0.17 | |
Graham Number |
47.29 | 54.79 | 53.05 | 54.81 | |
Earnings Yield |
5.01% | 10.45% | 8.78% | 5.44% | |
Free Cash Flow Yield |
4.88% | 9.10% | 6.53% | 2.90% | |
Revenue per Share |
7.14 | 6.96 | 7.13 | 9.16 | |
Operating CF per Share |
1.60 | 0.81 | 0.45 | 1.79 | |
Capex per Share |
(0.26) | (0.32) | (0.34) | (0.36) | |
Free Cash Flow per Share |
1.34 | 0.49 | 0.11 | 1.42 | |
Cash per Share |
11.34 | 11.12 | 9.89 | 10.50 | |
Shareholders Equity per Share |
28.59 | 28.63 | 27.61 | 26.60 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
28.59 | 28.63 | 27.61 | 26.60 | |
Free Cash Flow |
38.88 | 14.07 | 3.12 | 41.81 | |
Working Capital |
530.29 | 537.49 | 477.40 | 487.60 | |
Capital Expenditures |
(7.54) | (9.16) | (9.73) | (10.66) | |
Net Current Asset Value |
501.54 | 508.26 | 447.78 | 457.50 | |
EV/EBIT |
107.11 | 18.02 | 23.51 | 47.30 | |
Capex to Sales |
0.04 | 0.05 | 0.05 | 0.04 | |
Price to Operating Income |
127.29 | 23.77 | 28.85 | 53.16 | |
| Other line items | |||||
Average Receivables |
106.35 | 120.51 | 98.86 | 106.38 | |
Average Payables |
48.66 | 40.13 | 35.49 | 37.63 | |
Average Inventory |
160.37 | 146.04 | 132.98 | 112.71 | |
Average Assets |
880.37 | 864.09 | 821.09 | 857.85 | |
Average Common Equity |
746.70 | 751.70 | 714.04 | 735.43 |
Columns are period end dates · fundamentals updated 5 Nov 2026